Intralipid therapy for unexplained recurrent miscarriage and implantation failure: Case-series and literature review.

Introduction: In retrospective cohort study of women with unexplained recurrent implantation failure (RIF) and miscarriage (RM), we analyzed the efficacy and safety of intralipid therapy to obtain a live birth.

Patients And Methods: Women with unexplained RM and/or RIF were included from 2015 to 2018 from three French university hospitals.

Results: Among 187 women treated for unexplained recurrent miscarriages and implantation failures, 26 women with median age of 36 years (29-43) received intralipid therapy.